Drug intelligence / Profile preview

SiJiGanMao Tablet

Development stage: Unknown
Lead developer: Shanxi Buchang Pharmaceutical
Administration: Oral

Overview

SiJiGanMao Tablet is a Traditional Chinese Medicine (TCM) product developed and manufactured by Shanxi Buchang Pharmaceutical. It is formulated as a tablet and is indicated for the treatment of the common cold and influenza, particularly those characterized by symptoms such as fever, headache, nasal congestion, runny nose, cough, and sore throat. As a TCM, it typically functions by inducing diaphoresis to dispel wind and cold, and resolving the exterior. It is approved for use in China.

Brand names: SiJiGanMao Tablet
Other names: Sijiganmao PianFour Seasons Cold Tablet

Beyond the preview

Go deeper on SiJiGanMao Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SiJiGanMao Tablet.

Explore the full profile